Federal Health Policy Changes and Compounded GLP-1 Drugs One of the biggest Federal Health Policy Changes involves the FDA’s effort to limit large-scale compounding of semaglutide and tirzepatide. Brand-name medications such as: often cost over $1,000 monthly without insurance coverage. Compounded versions became popular because they were dramatically cheaper. Some patients paid: For many families, … Continue reading Federal Health Policy Changes: 9 Powerful Impacts on Patients